Journal Information
Vol. 93. Issue 4.
Pages 624 (1 July 2018)
Share
Share
Download PDF
More article options
Vol. 93. Issue 4.
Pages 624 (1 July 2018)
Open Access
Correspondence from Dr. Laila de Laguiche
Visits
4158
Lailade Laguiche1
1 Private clinic, Curitiba (PR), Brasil.
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Dear Editor

I was surprised to read the notice in our Annals 2017 number 92(6).1

SBD’s opinion sharing on time reduction and uniformization of the polychemotherapeutic treatment for Hansen’s disease in our country sounds to me somewhat hasty and not representative of the international scientific medical class.

I am a scholar on the subject and closely follow WHO’s and PAHO’s guidelines.

The new guidelines are: early diagnosis, epidemiological control of hotspots, reduction of the degree of disability and elimination of stigma. Changing or reducing the chemotherapeutic scheme is not considered. Rapid tests and post-exposure treatments for family members and contacts are being studied. Maybe some hope?

Those who, like me, work with Hansen’s disease know that a multibacillary does not become sterilized in 6 months and on many occasions, not even in 12 months... these are the scientific evidences from our daily dermatology practice.

This is a scientific conflict and we should always take precedence for the excellence of truth and replicability of clinical studies for new destinations in science.

The deficits in the clinical training of non-dermatologist colleagues and health professionals in general make the classification and adequate approach of these patients difficult. But we should not be guided by the simplest or shortest treatment, running the risk of harming our patient with catastrophic consequences and causing them sequelae to life. Primum non nocere.

Medical treatment is still free worldwide. This treatment already shows drug resistance in up to 16% of patients. Recurrences and treatment failures are frequent in the 6 national reference centers.  Clinical studies of alternative pharmacological treatments could also be of help to this disease.

So, how do we implement a treatment based on the same drugs, with a shorter time, in view of this picture of bacterial resistance of a disease that currently displays an epidemiological resurgence in a third of the national territory?

I believe in the ability and training of our scientists and hope that relevant scientific studies will still be described to substantiate this important decision in national public health”.

References
[1.]
RCS Cruz, S Bührer-Sékula, MLF Penna, GO Penna, S. Talhari.
Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.
An Bras Dermatol., 92(6) (2017), pp. 761-773
Copyright © 2018. Anais Brasileiros de Dermatologia
Download PDF
Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.